个体化治疗时代多靶点药物究竟何去何从——多靶点药物治疗非小细胞肺癌最新临床进展综述

Multi-targeted tyrosine kinase inhibitors (TKIs) play important roles in the treatment of non-small cell lung cancer (NSCLC). Recently, results of several large phase Ⅲ studies have been published, showing bittersweet efficacy of multi-targeted TKIs. In the era of personalized therapy, optimal use o...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 中国肺癌杂志编辑部 2011
Materias:
综述
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5999997/
https://www.ncbi.nlm.nih.gov/pubmed/22104223
http://dx.doi.org/10.3779/j.issn.1009-3419.2011.11.08
_version_ 1783331583577554944
collection PubMed
description Multi-targeted tyrosine kinase inhibitors (TKIs) play important roles in the treatment of non-small cell lung cancer (NSCLC). Recently, results of several large phase Ⅲ studies have been published, showing bittersweet efficacy of multi-targeted TKIs. In the era of personalized therapy, optimal use of multi-targeted TKIs is worthy of further investigation. In this review, we summarized current clinical development and future direction of multi-targeted TKIs in NSCLC..
format Online
Article
Text
id pubmed-5999997
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher 中国肺癌杂志编辑部
record_format MEDLINE/PubMed
spelling pubmed-59999972018-07-06 个体化治疗时代多靶点药物究竟何去何从——多靶点药物治疗非小细胞肺癌最新临床进展综述 Zhongguo Fei Ai Za Zhi 综述 Multi-targeted tyrosine kinase inhibitors (TKIs) play important roles in the treatment of non-small cell lung cancer (NSCLC). Recently, results of several large phase Ⅲ studies have been published, showing bittersweet efficacy of multi-targeted TKIs. In the era of personalized therapy, optimal use of multi-targeted TKIs is worthy of further investigation. In this review, we summarized current clinical development and future direction of multi-targeted TKIs in NSCLC.. 中国肺癌杂志编辑部 2011-11-20 /pmc/articles/PMC5999997/ /pubmed/22104223 http://dx.doi.org/10.3779/j.issn.1009-3419.2011.11.08 Text en 版权所有©《中国肺癌杂志》编辑部2011 https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/
spellingShingle 综述
个体化治疗时代多靶点药物究竟何去何从——多靶点药物治疗非小细胞肺癌最新临床进展综述
title 个体化治疗时代多靶点药物究竟何去何从——多靶点药物治疗非小细胞肺癌最新临床进展综述
title_full 个体化治疗时代多靶点药物究竟何去何从——多靶点药物治疗非小细胞肺癌最新临床进展综述
title_fullStr 个体化治疗时代多靶点药物究竟何去何从——多靶点药物治疗非小细胞肺癌最新临床进展综述
title_full_unstemmed 个体化治疗时代多靶点药物究竟何去何从——多靶点药物治疗非小细胞肺癌最新临床进展综述
title_short 个体化治疗时代多靶点药物究竟何去何从——多靶点药物治疗非小细胞肺癌最新临床进展综述
title_sort 个体化治疗时代多靶点药物究竟何去何从——多靶点药物治疗非小细胞肺癌最新临床进展综述
topic 综述
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5999997/
https://www.ncbi.nlm.nih.gov/pubmed/22104223
http://dx.doi.org/10.3779/j.issn.1009-3419.2011.11.08
work_keys_str_mv AT gètǐhuàzhìliáoshídàiduōbǎdiǎnyàowùjiūjìnghéqùhécóngduōbǎdiǎnyàowùzhìliáofēixiǎoxìbāofèiáizuìxīnlínchuángjìnzhǎnzōngshù

Ejemplares similares